Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Story

Isomorphic Labs Raises $5 Billion in Series C for AI Drug Design

AI summary

Isomorphic Labs, the Alphabet drug discovery company led by Demis Hassabis, raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, according to The Next Web. Andreessen Horowitz and other new investors joined, while Alphabet and existing investors participated; the company said the round was oversubscribed, but no independent evidence was supplied. Isomorphic plans to use the funding to advance IsoDDE toward clinical trials, expand into additional drug modalities and support more than 20 programmes.

In-depth insight

The financing provides substantial capital for Isomorphic Labs’ AI drug-design platform and clinical development, while the company’s valuation remains undisclosed and is only externally estimated at about $50 billion.

Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design
Demis Hassabis at the World Economic Forum in Davos, January 2025 Credit: World Economic Forum / Gabriel Lado / CC BY-NC-SA 2.0 via Flickr (cropped)
Image Credits
Demis Hassabis at the World Economic Forum in Davos, January 2025 Credit: World Economic Forum / Gabriel Lado / CC BY-NC-SA 2.0 via Flickr (cropped)

Isomorphic Labs, the Alphabet drug discovery company run by Demis Hassabis, has raised $5bn in a Series C round co-led by Greenoaks and Sequoia Capital. The company announced the round on Tuesday, six months after it raised $2.1bn in May.

#Isomorphic Labs#Alphabet#Greenoaks#Sequoia Capital#Andreessen Horowitz#Thrive Capital#MGX#GV#CapitalG#Temasek#UK Sovereign AI Fund#IsoDDE

Original · 2 min readRead the original
Group chat

No comments yet. Start the conversation.